A multinational research team of clinicians and scientists from South Korea and Singapore has published positive findings ...

The precise use of immunotherapy agents in locally advanced head and neck squamous cell carcinoma has not been clearly ...

随着研究的不断深入和治疗经验的积累，免疫治疗、靶向治疗与化疗的多种联合方案在恶性肿瘤治疗中取得了显著进展，极大地丰富了多种恶性肿瘤的治疗模式。目前，针对晚期BTC方面的联合治疗方案也在如火如荼地进行中，并已取得一系列令人振奋的研究结果，有望为更多BTC患者带来生存希望。

Professor Park Joon-sik of obstetrics and gynecology at Soonchunhyang University Bucheon Hospital announced on the 14th that ...

Five-year data from the KEYNOTE-048 trial support the use of pembrolizumab and pembrolizumab-chemotherapy as standards of care, researchers wrote.

近年来，随着对肿瘤生物学特性的深入认识，特别是肿瘤干细胞的发现以及免疫治疗的突破性进展，肿瘤领域迎来了前所未有的变革。在这一背景下，抑制剂和人源化单抗在肿瘤干细胞与免疫研究中的应用日益受到关注，并展现出巨大的潜力。AbMole多年来持续关注小分子抑制 ...

During a live event, Matthew Galsky, MD, discussed adjuvant nivolumab in muscle-invasive bladder cancer and the benefit in ...

Small Cell Lung Cancer Market Insights, Epidemiology, and Market Forecast-2034" report delivers an in-depth understanding of ...

Pilatus Biosciences, pioneering biologics targeting metabolic checkpoints, will present new research on its lead candidate, PLT012, at the American Association for Cancer Research (AACR) 2025 Annual ...

LARKSPUR, CA, USA I April 14, 2025 I Aulos™ Bioscience, an immuno-oncology company working to revolutionize cancer care through development of ...

AU-007, combined with Opdivo and low-dose aldesleukin, has entered a phase 2 melanoma trial, with early data showing activity ...

On March 28, the FDA approved Imfinzi for use in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by single-agent Imfinzi as adjuvant treatment after radical cystectomy, ...